Law360, New York (November 22, 2005, 12:00 AM EST) -- Astrazeneca AB has responded to Ranbaxy’s attempt to market a generic version of popular ulcer drug Nexium, filing a lawsuit in district court in New Jersey accusing the Indian drug maker of patent infringement.
The suit comes in response to an Abbreviated New Drug Application filed by Ranbaxy with the U.S. Food and Drug Administration, according to Astrazeneca. The suit was filed in the U.S. District Court for the District of New Jersey.
The suit claims infringement based on Ranbaxy’s stated intent to market a generic...
Ulcer Drug Patents Spark Court Battle
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
